Pharma Pulse 1/7/25: Updates Guidelines for T1D, Navigating Access/Reimbursement Through Uncertainty & more

Navigating Access and Reimbursement Through Uncertainty

A forum intended for HCPs, policy experts, and industry leaders addresses pressing obstacles facing this sector of the industry today.

Diabetes Association Updates Guidelines for Type 1 Diabetes

The updated guidelines from the American Diabetes Association emphasize the use of antibody-based screening for type 1 diabetes and recommend that physicians discuss potential use of Tzield, a monoclonal antibody approved to delay the onset of the symptoms of the disease.

US Surgeon General Calls for Cancer Warnings on Alcohol

Alcoholic drinks like beer and wine should carry warnings of their links to cancer, the US’s top doctor said, citing a lack of public awareness of the popular products’ health risks.

MilliporeSigma Acquires HUB Organoids Holding B.V., Expands Next-Gen Biology Portfolio

The Life Science business of Merck KGaA, Darmstadt, Germany, has acquired HUB Organoids B.V. (HUB), as announced by MilliporeSigma, the US and Canada business of Merck KGaA, Darmstadt, Germany in a December 17 announcement.

The acquisition, which closed on December 23, 2024, is a strategic step aligned with the company’s commitment to providing novel next-generation biology solutions to the life science industry, specifically by enabling wider access to HUB’s technology for faster and more effective drug development. Terms of the deal were not disclosed.

Amy Heath on LinkedIn

Effective and informed Business Development and Licensing (BD&L) teams are essential to the success of #biopharma manufacturers. A BD&L assessment without an expert analysis detailing how payers will evaluate and cover a potential new therapy can lead to dire unintended consequences.
At Formulary Insights—Powered by Petauri, we work with BD&L teams to ensure all evaluations are vetted through the critical #marketaccess lens, ensuring commercial success. Pharmaceutical Executive

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs